Related Experiment Video
Updated: Jun 5, 2026
A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination
Published on: June 25, 2014
Pancreatic β-Cell Mass as a Pharmacologic Target in Diabetes
Abstract:
While the prevalence of maternal While the prevalence of diabetes mellitus reaches epidemic proportions, most available treatments still focus on the symptoms of the disease, rather than the underlying pathology. Types 1 and 2 diabetes have in common a deficit in β-cell mass. In type 1 diabetes, auto-immune β-cell destruction leads to an absolute deficit in β-cells, while in type 2 diabetes, insulin resistance and β-cell dysfunction cause a functional deficit. More recently, however, it has been suggested that type 2 diabetes is also marked by an absolute deficit in β-cell mass, although a causal relationship has not yet been established. Overall β-cell mass reflects the balance between the dynamic processes of β-cell expansion, through proliferation and neogenesis, and β-cell loss via apoptosis. Given that β-cell mass can be modified significantly by altering the rate of any of these mechanisms, therapies that modulate β-cell expansion and loss have garnered recent interest. We review herein the current therapeutics under investigation as modulators of β-cell mass dynamics, and the basic research that supports these novel therapeutic targets.
Insights
Diabetes treatments often miss the root cause: a loss of beta-cell mass. New research explores therapies targeting beta-cell expansion and survival to address both type 1 and type 2 diabetes.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Cell Biology
Background:
- Diabetes mellitus is a growing epidemic, yet current treatments primarily manage symptoms, not underlying causes.
- Both type 1 and type 2 diabetes are characterized by a deficit in pancreatic beta-cell mass.
- Beta-cell mass is regulated by the balance between proliferation/neogenesis and apoptosis.
Purpose of the Study:
- To review current therapeutic strategies aimed at modulating beta-cell mass dynamics.
- To highlight novel therapeutic targets based on recent basic research.
Main Methods:
- Literature review of ongoing research into diabetes therapeutics.
- Analysis of studies investigating mechanisms of beta-cell expansion and loss.
Main Results:
- Existing treatments for diabetes mellitus largely focus on symptom management.
- Emerging therapies investigate modulating beta-cell expansion and apoptosis.
- Type 2 diabetes may also involve an absolute deficit in beta-cell mass.
Conclusions:
- Modulating beta-cell mass dynamics presents a promising therapeutic avenue for diabetes.
- Targeting beta-cell expansion and survival could address the core pathology of both diabetes types.
- Further research into the basic science of beta-cell mass regulation is crucial for developing effective treatments.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are co-secreted in...
01:36Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...
01:24Type II Diabetes II: Pathophysiology